GoAI
Get started
Creative Medical Technology Holdings, Inc. logo

Creative Medical Technology Holdings, Inc.

CELZ

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$1.31

+$0.03 · +2.34%

Aug 21, 4:00 PM ET

CELZ company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

43

Fair Value

Momentum

18

Strong Down

Sentiment

55

Mixed

Risk resilience

24

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Creative Medical Technology Holdings, Inc., a biotechnology firm based in Phoenix, Arizona, specializes in advancing adult stem cell treatments. The company's core focus spans several medical fields, including immunology, urology, orthopedics, and neurology. Among its therapeutic offerings are CaverStem, designed to address erectile dysfunction; FemCelz, which aims to restore genital sensitivity and alleviate dryness; StemSpine, developed to treat chronic lower back pain; ImmCelz, intended for stroke patients; and OvaStem, a solution for female infertility.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Timothy Warbington
Listed since
Nov 6, 2015
Employees
4

Market position

Day range

Current $1.31

52-week range

Current $1.31

Open
$1.265
Previous close
$1.28
Volume
549.05K
0.08× average
Average volume
6.77M
Average daily volume
Market cap
3.38M USD
Beta
1.94
Market reference 1
50-day average
$1.2187
+7.49% above average
200-day average
$1.9453
-32.66% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-2.52M USD
P/E (TTM)
-0.66×
P/B (TTM)
0.56×
P/S (TTM)
1,126.89×
EV / EBITDA
0.42×
Earnings yield
-128.37%
Free cash flow yield
-125.40%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-1732.37%
Operating margin
-208004.40%
Net margin
-201355.37%
Return on equity
-79.78%
Return on assets
-76.77%
Return on invested capital
-81.48%

Financial health

Debt / equity
0×
Current ratio
25.97×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends34320%-15389%-65098%-114808%Gross margin, FY2021: 45.36%Gross margin, FY2022: 67.84%Gross margin, FY2023: 60.00%Gross margin, FY2024: 60.00%Gross margin, FY2025: 63.43%Operating margin, FY2021: -3562.17%Operating margin, FY2022: -11562.50%Operating margin, FY2023: -62445.91%Operating margin, FY2024: -52216.92%Operating margin, FY2025: -102380.23%Net margin, FY2021: 21892.75%Net margin, FY2022: -11449.26%Net margin, FY2023: -58739.71%Net margin, FY2024: -49940.74%Net margin, FY2025: -99916.80%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 45.36%. Gross margin FY2022 67.84%. Gross margin FY2023 60.00%. Gross margin FY2024 60.00%. Gross margin FY2025 63.43%. Operating margin FY2021 -3562.17%. Operating margin FY2022 -11562.50%. Operating margin FY2023 -62445.91%. Operating margin FY2024 -52216.92%. Operating margin FY2025 -102380.23%. Net margin FY2021 21892.75%. Net margin FY2022 -11449.26%. Net margin FY2023 -58739.71%. Net margin FY2024 -49940.74%. Net margin FY2025 -99916.80%.

Income trends

Revenue

6K USD-45.45%

Operating income

−6.14M USD-6.95%

Net income

−6M USD-9.13%
Income trends across reported periods22.16M USD10.37M USD−1.41M USD−13.19M USDRevenue, FY2021: 87.75K USDRevenue, FY2022: 88.6K USDRevenue, FY2023: 9K USDRevenue, FY2024: 11K USDRevenue, FY2025: 6K USDOperating income, FY2021: −3.13M USDOperating income, FY2022: −10.24M USDOperating income, FY2023: −5.62M USDOperating income, FY2024: −5.74M USDOperating income, FY2025: −6.14M USDNet income, FY2021: 19.21M USDNet income, FY2022: −10.14M USDNet income, FY2023: −5.29M USDNet income, FY2024: −5.49M USDNet income, FY2025: −6M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 87.75K USD. Revenue FY2022 88.6K USD. Revenue FY2023 9K USD. Revenue FY2024 11K USD. Revenue FY2025 6K USD. Operating income FY2021 −3.13M USD. Operating income FY2022 −10.24M USD. Operating income FY2023 −5.62M USD. Operating income FY2024 −5.74M USD. Operating income FY2025 −6.14M USD. Net income FY2021 19.21M USD. Net income FY2022 −10.14M USD. Net income FY2023 −5.29M USD. Net income FY2024 −5.49M USD. Net income FY2025 −6M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue6K USD11K USD9K USD88.6K USD87.75K USD
Cost of goods sold2.19K USD4.4K USD3.6K USD28.49K USD47.95K USD
Gross profit3.81K USD6.6K USD5.4K USD60.11K USD39.81K USD
Research and development2.26M USD2.4M USD1.97M USD6.27M USD109.18K USD
Selling, general, and administrative3.76M USD3.24M USD3.56M USD3.94M USD2.96M USD
Operating expenses6.15M USD5.75M USD5.63M USD10.3M USD3.17M USD
Interest income147.81K USD250.38K USD333.56K USD100.33K USD—
Interest expense————4.28M USD
Depreciation and amortization123.33K USD110.45K USD94.58K USD92.08K USD92.08K USD
Operating income−6.14M USD−5.74M USD−5.62M USD−10.24M USD−3.13M USD
Net income−6M USD−5.49M USD−5.29M USD−10.14M USD19.21M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
36%
4 beats, 6 misses, 1 met estimate
Average EPS surprise
-20.30%
11 comparable reports
Latest EPS result
-0.41
Estimate -0.39 · Miss by 5.13%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.2-0.53-0.86-1.19Q1 '25MissQ2 '25MissQ3 '25BeatQ4 '25MetQ1 '26MissQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 14, 2025: actual -1.12, estimate -0.63, surprise -77.78%, Miss. Q2 2025, reported May 9, 2025: actual -0.83, estimate -0.52, surprise -59.62%, Miss. Q3 2025, reported Aug 8, 2025: actual -0.48, estimate -0.63, surprise +23.81%, Beat. Q4 2025, reported Nov 7, 2025: actual -0.48, estimate -0.48, surprise 0.00%, Met estimate. Q1 2026, reported Mar 20, 2026: actual -0.8, estimate -0.37, surprise -116.22%, Miss. Q2 2026, reported May 8, 2026: actual -0.38, estimate -0.39, surprise +2.56%, Beat. Q3 2026, reported Aug 7, 2026: actual -0.41, estimate -0.39, surprise -5.13%, Miss. Q4 2026, reported Nov 6, 2026: actual —, estimate -0.24, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates8.4K6.47K4.53K2.6KQ1 '24No estimateQ3 '24No estimateQ1 '25No estimateQ2 '25No estimateQ1 '26Met
Q1 2024, reported Mar 22, 2024: actual 3K USD, estimate —, surprise —, Comparison unavailable. Q3 2024, reported Aug 9, 2024: actual 8K USD, estimate —, surprise —, Comparison unavailable. Q1 2025, reported Mar 14, 2025: actual 3K USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 9, 2025: actual 3K USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 20, 2026: actual 3K USD, estimate 3K USD, surprise 0.00%, Met estimate.

Corporate actions

Corporate action history

Stock split

Effective Jun 12, 2023

1:10

Stock split

Effective Nov 10, 2021

1:500

Stock split

Effective Feb 3, 2020

1:150

CELZ peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding CELZ

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
13.51K
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%

Continue in GoAI

Research CELZ

research.disclaimer